PubMed=10640966; DOI=10.1002/(SICI)1097-0142(20000115)88:2<344::AID-CNCR14>3.0.CO;2-6
Fiedler W., Henke R.P., Ergun S., Schumacher U., Gehling U.M., Vohwinkel G., Kilic N., Hossfeld D.K.
Derivation of a new hematopoietic cell line with endothelial features from a patient with transformed myeloproliferative syndrome: a case report.
Cancer 88:344-351(2000)

PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)

PubMed=22829968; DOI=10.1038/bcj.2012.11
Buors C., Douet-Guilbert N., Morel F., Lecucq L., Cassinat B., Ugo V.
Clonal evolution in UKE-1 cell line leading to an increase in JAK2 copy number.
Blood Cancer J. 2:E66-E66(2012)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)